Transcranial direct current stimulation for OCD: video abstract ID 184839 скачать в хорошем качестве

Transcranial direct current stimulation for OCD: video abstract ID 184839

Video abstract of review type paper “Transcranial direct current stimulation for Obsessive Compulsive Disorder: patient selection and perspectives” published in the open access journal Neuropsychiatric Disease and Treatment by authors da Silva RMF, Brunoni AR, Miguel EC et al. Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation technique that has been increasingly examined as an alternative treatment modality for Obsessive-Compulsive Disorder (OCD), due to its low costs, ease of use, and portability. Previous studies have suggested that tDCS may achieve a reasonably good response and present a safe tolerability profile. However, at this point there is not strong evidence for the use of this modality of treatment. Considering that OCD is very heterogeneous with regard to clinical presentation, clinical severity and comorbidities, we have conducted a systematic review of studies on tDCS for OCD aiming to evaluate the clinical characteristics of the selected patients and to discuss perspectives for future studies. A literature search was conducted from inception until March 2019 at PubMed/MedLine and Scielo using the following keywords: “tdcs” or “transcranial direct current stimulation” and “obsessive compulsive disorder”. Out of 45 manuscripts, twelve were included. Most of the included studies are uncontrolled. A few controlled studies reported improvement of OCD, but some limitations need to be considered. Our main findings were that the selected patients were adults with severe OCD and psychiatric comorbidities, medicated at the time of assessment and resistant to at least one previous conventional treatment. We could not find any studies including specific populations such as adolescents, elderly, pregnant and breastfeeding participants. Similarly, the potential use of tDCS has not been tested in patients with less severe OCD, as a first treatment option, or for those who do not tolerate pharmacological treatments. These opportunities should be explored in future controlled trials. Read the full paper here https://www.dovepress.com/transcrania...